Azenta, Inc. $AZTA Shares Sold by Quantinno Capital Management LP

Quantinno Capital Management LP lowered its stake in Azenta, Inc. (NASDAQ:AZTA) by 63.3% during the first quarter, HoldingsChannel reports. The firm owned 226,690 shares of the company’s stock after selling 391,358 shares during the period. Quantinno Capital Management LP’s holdings in Azenta were worth $4,790,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Integrated Wealth Concepts LLC acquired a new stake in shares of Azenta during the 1st quarter valued at about $435,000. Millennium Management LLC increased its holdings in Azenta by 214.8% in the first quarter. Millennium Management LLC now owns 340,580 shares of the company’s stock worth $11,798,000 after buying an additional 232,405 shares during the last quarter. Empowered Funds LLC increased its holdings in Azenta by 10.5% in the first quarter. Empowered Funds LLC now owns 6,482 shares of the company’s stock worth $225,000 after buying an additional 618 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in Azenta by 17.8% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 201,337 shares of the company’s stock valued at $6,974,000 after acquiring an additional 30,492 shares in the last quarter. Finally, Creative Planning acquired a new stake in Azenta in the second quarter valued at approximately $270,000. Hedge funds and other institutional investors own 99.08% of the company’s stock.

Azenta Stock Performance

Shares of NASDAQ AZTA opened at $30.74 on Friday. The business’s 50-day simple moving average is $25.44 and its 200-day simple moving average is $25.48. Azenta, Inc. has a 52 week low of $15.93 and a 52 week high of $41.73. The firm has a market cap of $1.42 billion, a price-to-earnings ratio of -11.14 and a beta of 1.37.

Azenta (NASDAQ:AZTA) last posted its earnings results on Tuesday, August 4th. The company reported $0.16 earnings per share for the quarter, topping the consensus estimate of $0.11 by $0.05. The firm had revenue of $161.18 million during the quarter, compared to analyst estimates of $149.31 million. Azenta had a positive return on equity of 1.18% and a negative net margin of 20.63%.

Analyst Upgrades and Downgrades

Several research firms have commented on AZTA. Needham & Company LLC boosted their target price on shares of Azenta from $33.00 to $37.00 and gave the stock a “buy” rating in a research report on Wednesday. Weiss Ratings upgraded shares of Azenta from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, July 15th. Four analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Azenta has an average rating of “Hold” and an average target price of $41.20.

Azenta Company Profile

Azenta, Inc (NASDAQ: AZTA) is a life sciences technology company specializing in sample management, cryogenic storage and genomic services for research and clinical applications. Formerly the Life Sciences division of Brooks Automation, Azenta provides integrated solutions that enable customers to store, track and analyze biological samples with high levels of automation, data integrity and efficiency. Its offerings span automated storage systems, biorepository management software and end‐to‐end sample tracking workflows.

In addition to hardware and informatics platforms for sample storage, Azenta’s Genomics business delivers next‐generation sequencing (NGS), DNA synthesis, and molecular biology services.